Clinical trials: Hearing and Vision Loss

Angiokeratomas, Chronic Kidney Disease

Biomarker for Patients With Fabry Disease (BioFabry)

• Withdrawn
• Age: 2 months and older
• Observational study

Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood

Conditions

Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss

Trial name

BioFabry (NCT02778295)

Where

3 sites in Germany, India and 1 more

Sponsor

CENTOGENE GmbH Rostock